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Abstract: Although recent data suggest aristolochic acid as a putative cause of Balkan 
endemic nephropathy (BEN), evidence also exists in favor of ochratoxin A (OTA) 
exposure as risk factor for the disease. The potential role of xenobiotic metabolizing 
enzymes, such as the glutathione transferases (GSTs), in OTA biotransformation is based 
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on OTA glutathione adducts (OTHQ-SG and OTB-SG) in blood and urine of BEN 
patients. We aimed to analyze the association between common GSTA1, GSTM1, GSTT1, 
and GSTP1 polymorphisms and BEN susceptibility, and thereafter performed an in silico 
simulation of particular GST enzymes potentially involved in OTA transformations. 
GSTA1, GSTM1, GSTT1 and GSTP1 genotypes were determined in 207 BEN patients and 
138 non-BEN healthy individuals from endemic regions by polymerase chain reaction 
(PCR). Molecular modeling in silico was performed for GSTA1 protein. Among the GST 
polymorphisms tested, only GSTA1 was significantly associated with a higher risk of BEN. 
Namely, carriers of the GSTA1*B gene variant, associated with lower transcriptional 
activation, were at a 1.6-fold higher BEN risk than those carrying the homozygous 
GSTA1*A/*A genotype (OR = 1.6; p = 0.037). In in silico modeling, we found four 
structures, two OTB-SG and two OTHQ-SG, bound in a GSTA1 monomer. We found that 
GSTA1 polymorphism was associated with increased risk of BEN, and suggested, 
according to the in silico simulation, that GSTA1-1 might be involved in catalyzing the 
formation of OTHQ-SG and OTB-SG conjugates. 
Keywords: Balkan endemic nephropathy; biotransformation; glutathione transferase A1; 
ochratoxin A; polymorphism 
 
1. Introduction 
Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial kidney disease. This nephropathy 
is recognized as endemic in certain rural areas of Serbia, Bosnia, Croatia, Bulgaria, and Romania [1]. 
There is an ongoing discussion in the literature whether aristolochic acid (AA) or ochratoxin A (OTA) 
(Chart 1) are linked to BEN. In favor of the hypothesis that environmental exposure to OTA is a 
significant risk factor for the development of the disease is the detection of OTA-specific DNA 
adducts OTA-dG and OTA-O-3'-dGMP (Chart 2) in BEN patients from Serbia, Croatia, and  
Bulgaria [2,3], as well as in Bulgarian farmer suffering from BEN and upper urinary tract tumors [3]. 
One of the common features of BEN is that not all individuals exposed to OTA suffer from 
nephropathy and cancer [4], suggesting individual susceptibility as a risk factor. Besides differences in 
the cumulated dose of OTA and the duration of OTA intake, differences in OTA detoxification could 
be the reason for this individual susceptibility. Many genes of enzymes metabolizing xenobiotics are 
known to exist in variant forms of polymorphisms and appear to be important determinants of risk of 
diseases [5]. Thus, the identification of enzymes principally involved in the metabolism (i.e., activation 
and/or detoxification) of OTA in humans and detailed knowledge of their catalytic specificities is of 
major importance. 
The metabolic fate of OTA in both animals and humans evolved in two directions. One, which 
comprises hydrolysis [6] (ochratoxin α-OTα, Chart 1) and oxidations [7] (Products 1, 2, 3, Chart 1). 
The second pathways comprises bioactivation, which could lead either to detoxification or to 
genotoxicity by this mycotoxin [8]. There is strong evidence suggesting a key role of  
carboxypeptidase A, which converts OTA into its non-toxic metabolite OTα and phenylalanine. 
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However, it seems that due to the slow metabolic rate, a small portion of OTA undergoes 
transformation into hydroquinone and quinone derivatives (OTHQ and OTQ respectively, Chart 2) 
after bioactivation. Bioactivation of OTA into OTHQ/ OTQ derivatives is supposed to be mediated by 
CYP1A1 and 3A4 in the liver [8], and probably by CYP3A5 in the kidneys [9]. They are further 
transformed into a glutathione conjugate (OTHQ-SG, Chart 2), as a result covalent bond formation 
between C6 of OTQ and a thiol-group of the reduced glutathione. Existence of this pathway in humans 
was supported by evidence of OTHQ-SG presence in blood and urine samples of BEN patients. 
Furthermore, in addition to OTHQ-SG, very recently the presence of OTB-SG (Chart 2) conjugates 
has also been shown in this biological material [7,10]. 
Chart 1. Structures of aristolochic acid (AA), ochratoxin (OTA) and its metabolites. 
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Chart 2. Ochratoxin (OTA) metabolites and OTA-specific DNA adducts (OTA-dG  
and OTA-O-3'-dGMP); OTHQ-ochratoxin hydroquinone, OTQ-ochratoxin quinone,  
OTHQ-SG-ochratoxin hydroquinone conjugated with glutathione. 
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While both OTHQ-SG and OTB-SG appear to be stable markers of OTA exposure, it remains 
controversial whether these GSH metabolites are more or less toxic than OTA itself. It should be 
emphasized that both reactions, which result in the formation of OTHQ-SG and OTB-SG conjugates 
could be catalyzed by members of the glutathione transferases (GST) family. Despite the fact that 
GSTs might be involved in various pathways of OTA metabolism and make up 3%–5% and 1% of the 
total protein in the liver and kidney, respectively [11], the distinct role of these enzymes in OTA 
metabolism, especially with regard to BEN susceptibility, has been underexplored. 
The family of cytosolic GSTs is comprised of different classes, including Alpha (GSTA), Mu 
(GSTM), Pi (GSTP), and Theta (GSTT) classes. The active site can be divided into two sub-sites:  
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a polar site for binding GSH (G-site) and an adjacent hydrophobic region for electrophile substrates  
(H-site) [12]. GSTs show different abilities to bind xenobiotics, from promiscuity to high specificity. 
Approximately half of the general population lacks GSTM1-1 enzyme activity, due to a homozygous 
deletion of the GSTM1 gene [13]. In the case of the GSTT1 gene, homozygous deletion is present in 
about 20% of Caucasians, resulting in the lack of GSTT1-1 enzyme activity [14]. Single-nucleotide 
polymorphism (SNP), leading to amino acid substitution from isoleucine (Ile) to valine (Val) [15], 
changes the catalytic activity of the GSTP1-1 enzyme [16]. GSTA1 polymorphism is represented by 
three, apparently linked, SNPs, which result in differential expression with lower transcriptional 
activation of the variant GSTA1*B (-567G, -69T, -52A) than the common GSTA1*A allele  
(-567T, -69C, -52G) [17]. Since GSTs have potential to conjugate OTA and its metabolites on one 
hand, and reduce free radicals that originate from OTA metabolites on the other, it is possible that GST 
genotype variations, with consequential absent or lower enzyme activities, may modify susceptibility 
to BEN. So far, the data on association between BEN and GST polymorphisms are scarce. This has 
prompted us to assess whether the common polymorphisms in GSTA1, GSTM1, GSTT1, and GSTP1 
are associated with susceptibility to BEN. 
We found that GSTA1 polymorphism was associated with increased risk of BEN, and examined  
in silico the capabilities of GSTA1 for acceptance of large substrates like OTHQ and reactive OTA 
metabolite into H-site and production of OTHQ-SG and OTB-SG conjugates. As result it was 
suggested that GSTA1-1, as the most promiscuous GST enzyme might be involved in the formation of 
OTHQ-SG and OTB-SG conjugates. 
2. Results and Discussion 
Demographic characteristics of patients and controls included in the study are shown in Table 1.  
As presented, there were no statistically significant differences with respect to age and gender. 
Table 1. Demographic characteristics of Balkan endemic nephropathy (BEN) cases  
and controls. 
Demographic characteristics Cases Controls p value 
Sex   0.134 
Male n (%) 116 (56) 66 (48)  
Female n (%) 91 (44) 72 (52)  
Age    
Mean ± SD 70.60 ± 6.54 69.33 ± 9.98 0.153 
n, number of cases or controls. 
The distribution of frequencies of GST genotypes in BEN patients and controls is presented in  
Table 2. The obtained distribution of allelic frequencies of GSTA1 and GSTP1 genes was consistent 
with the Hardy-Weinberg equilibrium (HWE) in both cases and controls (GSTA1: p = 0.429 for cases, 
p = 0.135 for controls; GSTP1: p = 0.539 for cases, p = 0.521 for controls). On the other hand, in the 
case of GSTM1 and GSTT1 polymorphisms, HWE was not determined, since the methods used could 
not distinguish between homozygous and heterozygous genotypes. The results obtained showed that 
GST genotype distribution among healthy subjects in endemic regions did not differ from those 
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reported in healthy subjects living in non-endemic regions [18,19]. When the frequency of GSTA1, 
GSTM1, GSTP1, and GSTT1 genotypes was analyzed in healthy subjects who lived in endemic regions 
and compared to those in healthy subjects who lived in non-endemic regions, no significant difference 
was obtained (data not shown). 
Table 2. GSTA1, GSTM1, GSTT1 and GSTP1 genotypes in relation to the risk of BEN. 
Genotypes of GST Cases n (%) Controls n (%) OR 
a
 with 95% CI p value 
GSTA1 C-69T     
*A/*A 58 (28) 53 (39) 1.0 b  
*A/*B 110 (53) 57 (41) 1.8 (1.1–2.9) 0.021 
*B/*B 39 (19) 28 (20) 1.3 (0.7–2.4) 0.377 
*A/*B + *B/*B 149 (72) 85 (61) 1.6 (1.0–2.6) 0.037 
GSTM1     
active c 115 (56) 75 (54) 1.0 b  
null d  92 (44) 63 (46) 0.9 (0.6–1.5)  0.790 
GSTT1     
active c 168 (81) 100 (72) 1.5 (0.9–2.5) 0.126 
null d  39 (19) 38 (28) 1.0 b   
GSTP1 A1578G     
Ile/Ile 97 (47) 62 (45) 1.0 b  
Ile/Val 92 (45) 57 (42) 1.0 (0.6–1.6) 0.953 
Val/Val 16 (8) 18 (13) 0.6 (0.3–1.2) 0.142 
Ile/Val + Val/Val 108 (53) 75 (55) 0.9 (0.6–1.4) 0.666 
n, number of cases or controls; OR, odds ratio, 95%; CI, confidence interval; a adjusted by age and gender;  
b reference group; c active if at least one active allele present; d null if no active allele present. 
As presented in Table 2, a significant association between the GST genotype and the risk of BEN 
development was found only for the GSTA1 polymorphism. Namely, individuals with GSTA1 *A/*B or 
*B/*B genotype were at a 1.6-fold higher risk of BEN than individuals carrying the homozygous 
GSTA1*A/*A genotype (OR = 1.6; CI = 1.0–2.6; p = 0.037). 
Regarding GSTM1 polymorphism, no significant difference between active/null genotype 
distribution among cases and controls was obtained. Thus, individuals carrying GSTM1 null genotype 
were at a similar risk of BEN as those with GSTM1 active genotype (OR = 0.9; CI = 0.6–1.5; p = 0.790). 
Although in the case of GSTT1 polymorphism, the frequency of the GSTT1 active genotype was 
higher in BEN patients than in controls (81% vs. 72%, respectively, p = 0.057) and the risk of BEN 
was 1.5 times higher in individuals with GSTT1 active genotype in comparison to GSTT1 null 
individuals, statistical significance in terms of BEN risk was not reached (OR = 1.5; CI = 0.9–2.5;  
p = 0.126). 
Results of GSTP1 polymorphism in patients with BEN have shown lack of association between 
GSTP1 genotype and risk of BEN. The wild-type GSTP1 genotype (Ile/Ile) was found as the most 
common in both patients and controls. Although in BEN patients, the frequency of the Val/Val 
genotype was slightly lower in comparison to controls (8% vs. 13%, respectively) and it seemed that 
this allele might have some effect on decreasing the risk of BEN, statistical significance was not reached 
(OR = 0.6; CI = 0.3–1.2; p = 0.142). 
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We further analyzed the combined effect of GST genotypes on the risk of BEN. The results 
obtained show that when GSTA1 genotypes are analyzed in combination with GSTT1 genotypes  
(Table 3), the highest risk of BEN occurrence is obtained in homozygous and heterozygous carriers of 
mutant GSTA1*B allele with the GSTT1 active genotype (OR = 2.3; CI = 1.0–5.3; p = 0.046). 
Table 3. Combined effects of GSTA1 with GSTT1 genotypes in relation to the risk of BEN. 
Genotypes 
GSTA1 
*A/*A *A/*B+*B/*B 
GSTT1 active a   
Ca/Co 46/38 122/62 
OR b (95% CI) 1.4 (0.6–3.4) 2.3 (1.0–5.3) c 
GSTT1 null d   
Ca/Co 12/15 27/23 
OR b (95% CI) 1.0 e 1.5 (0.6–3.9) 
OR, odds ratio, 95%; CI, confidence interval; Ca, number of patients; Co, number of controls; a active if at 
least one active allele present; b Adjusted by age and gender; c Statistically significant difference when 
compared with the reference group; d null if no active allele present; e reference group. 
As the result of in silico modeling, we obtained four structures, two for OTB-SG (A1 and A2) and 
two for OTHQ-SG (B1 and B2), bound in a GSTA1 monomer. Structures of ligands, which were 
placed in the binding site, are given on Figure 1. The structures of protein monomer was superimposed 
with structures of bound conjugates. GSTA1 protein is able to bind all four conjugates without 
significant changes in its structure (Figure 2 and Figures S1–S3, free/ligand protein structure is colored 
in cyan). The main changes are in the position of the two upper helices that are mobile (C-terminal 
helix 8, colored in magenta). The total potential energies of all the structures after the final 
minimization are given in Table S1. 
Figure 1. Three dimensional (3D) structures of the glutathione bound OTA in glutathione 
transferase A1-1. Possible structures of OTB-SG (A1 and A2), possible structures of  
OTHQ-SG (B1 and B2). 
 
A1 A2 
B1 B2 
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Figure 2. Superposition of glutathione transferase A1 (GSTA1) monomer with or without 
OTB-SG conjugate (A1). Free/ligand protein structure is colored in cyan. 
 
The results of this study, performed in 207 BEN patients and 138 non-BEN individuals from an 
endemic region, have shown that carriers of at least one GSTA1*B lower expression allele 
independently and in combination with the GSTT1 active allele are at higher risk of BEN development. 
The other two common GST polymorphisms tested, GSTM1 and GSTP1, were not significantly 
associated with BEN. In silico analysis showed that GSTA1 might be involved in catalyzing reactions 
of OTA metabolites with GSH. 
Our hypothesis that GST polymorphisms might result in differential susceptibility to BEN is based 
on the fact that GSTs catalyze several types of reactions that may be relevant for metabolism of OTA, 
one of the putative causes of BEN. It should be noted that until now only two studies have investigated 
the association between common GST gene variants and BEN risk. Andonova et al. [20] determined 
GSTM1, GSTT1, and GSTP1 polymorphisms in 54 BEN patients and 104 endemic controls and found 
GSTM1 active to be more prevalent among patients than controls. In another Bulgarian study, which 
was performed in 95 BEN patients and 112 non-endemic controls, the frequency of the GSTM1 active 
genotype was also higher in BEN patients than in controls, but did not reach statistical  
significance [21]. The results of our study, obtained in a much larger cohort of BEN patients, failed to 
show any difference in the distribution of GSTM1 gene variants between patients and controls, 
suggesting that this member of cytosolic GSTs is probably not involved in the metabolism of 
compounds responsible for BEN occurrence. It should be emphasized that regarding active GST gene 
variants tested in this study, only the GSTT1 active genotype was more frequent among BEN patients 
than controls. The risk of BEN was 1.5 times higher in persons with GSTT1 active genotype in 
comparison to GSTT1 null individuals, but this OR did not reach statistical difference. Our results are 
in accordance with data of Lebrun et al. [22], who pointed out the role of GSTT1 polymorphism in the 
extent of DNA damage induced by OTA. Namely, the GSTT1 active genotype was more frequently 
observed in the group of human donors of urothelial cells with DNA damage compared to a subgroup 
without DNA damage, both treated with OTA. In addition, the GSTT1 active genotype is frequently 
associated with exposure to occupational hazards, such as trichloroethylene TCE [23], smoking  
habits [24], and pesticides [25]. Although the fact that the GSTT1 active genotype confers the risk of 
BEN, the GSTT1-1 mediated conjugation of OTA with GSH into OTB-SG seems to be hardly 
possible. Namely, due to the hindered GSTT1 active site [26], large molecules like OTA cannot be 
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accommodated. Therefore, the role of GSTT1 polymorphism in ochratoxin nephrotoxicity still has to 
be clarified. 
The most prominent result of our study is that the presence of the GSTA1 gene variant, which 
results in lower transcriptional activation, is associated with a higher risk of BEN. It should be noted 
that the presence of two mutant GSTA1*B alleles results in a four times lower expression of this 
enzyme in the liver. GSTA1-1 is one of the most promiscuous GST enzymes with wide substrate 
specificity. It catalyses basically two types of reactions including conjugation with GSH and 
peroxidase reactions, in which GSH acts as a co-substrate to reduce organic hydro-peroxides.  
GSTA1-1 acts as a key liver cytosolic enzyme regarding GSH-dependent detoxification and 
antioxidant protection, especially in GSTM1 null individuals who do not express GSTM1-1 protein. 
Similarly, GSTA1-1 plays a fundamental role in renal tissue protection, from endproducts of both 
endogenous and exogenous compounds metabolisms, specifically in proximal tubules, where it is 
abundantly expressed [27]. Regarding OTA nephrotoxicity, it seems that both GSH-conjugation and 
antioxidant defense catalyzed by GSTA1-1 might play distinct roles in the kidney. The reactions 
mediated by GSTA1-1 are supposed to result in lower OTA toxicity. Therefore, it seems reasonable to 
assume that GSTA1-1 is directly involved in the conjugation of OTA or its metabolite. Having in mind 
that higher expression of GSTA1-1 in individuals with the GSTA1*A/*A genotype is associated with 
lower BEN risk. Therefore, we assumed that GSTA1-1 would most probably catalyze OTB-SG,  
as well as the formation of OTHQ-SG (Chart 2). Indeed, based on our in silico analysis, both covalent 
adducts could be obtained as GSTA1-1 products. 
The protective role of GSTA1-1 in terms of OTA toxicity and BEN risk is much easier to explain in 
the context of powerful antioxidant activity of GSTA1-1. Recent and most recent studies clearly 
establish a link between oxidative stress and OTA metabolism [28–30]. Thus, it seems that OTA 
influences both increased free radical production and decreased the gene expression of enzymes 
involved in glutathione synthesis and utilization [31,32]. Among OTA metabolites, OTHQ exerts 
strong pro-oxidant activity. Like other hydroquinones, OTHQ undergoes oxidation to generate 
superoxide and the quinone electrophile OTQ [10]. In the human renal proximal tubular epithelial cell 
line (HK-2), it was found that OTA treatment led to the release of reactive oxygen species and the 
increase of 8-hydroxydeoxyguanosine, an important biomarker of oxidative DNA damage [33]. 
Therefore, it seems reasonable to assume that the lack of GSTA1-1 antioxidant activity in conditions 
of chronic OTA exposure would lead to increased oxidative stress in kidney tissue. In this line, our 
data are in favor of the recent hypothesis of Cavin et al. [34], who supposed that failure of antioxidant 
protection mediated by GSTs promoted OTA-induced toxicity and oxidative stress. Moreover, the 
same group showed that OTA itself, at concentrations that are manifold higher than those detected in 
human and animal plasma, down-regulates overall GST expression and activity by inhibition of redox 
sensitive erythroid 2-like 2 (Nrf2) transcription factor in the kidney tubules cell line LLC-PK1 [35]. 
Nrf2 inhibition results in down-regulated expression of key enzymes of glutathione synthesis and 
metabolism, such as glutamine-cysteine ligase (GCL) and GSTP1-1 [31,36]. Although Nrf2 is not 
involved in the regulation of GSTA1 expression [37], a decreased GSTA1-1 protein level of GSTA1*B 
homozygotes might deepen the prooxidant-antioxidant disbalance in BEN. In the future, it would be 
important to address whether these individuals exhibit higher oxidative stress and if treatment with 
antioxidants (e.g., intact glutathione) could slowdown BEN progression. It should be emphasized that 
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in addition to its catalytic role, GSTA1-1 has also been shown to exhibit several non-catalytic 
functions, among which its anti-apoptotic activity has recently started to emerge, especially in context 
of anti-tumor drug resistance. In the view of the pathological changes that occur in the course of BEN 
progression, such as cell shrinking, tubular atrophy, and diffuse fibrosis of cortical interstitium, which 
further lead to reduction in the size of the kidney and increased apoptosis [38,39], lowered GSTA1-1 
expression would be expected to result in more apoptosis. GSTA1-1 acts as modulator of  
mitogen-activated protein kinase signal transduction pathways via a mechanism involving  
protein-protein interactions. GSTA1-1 forms complexes with c-Jun N-terminal kinase (JNK) and 
modifies JNK activation during cellular stress, but the factors that influence complex association and 
dissociation are unknown. Very recently, it has been suggested that the mechanism of  
menadione-induced JNK activation involves the production of reactive oxygen species, likely 
superoxide anion, and intracellular GSH levels play an important role in preventing GSTA1-1-JNK 
complex dissociation, subsequent JNK activation, and induction of cytotoxicity [40]. Having in mind 
the presence of pro-oxidant OTA derivatives, as well as increased oxidative stress in BEN, such 
mechanisms might also take place in the case of BEN progression. Results of Romero et al. [41] have 
indicated that GSTA1-1 suppresses activation of apoptotic JNK signaling by a pro-inflammatory 
cytokine and oxidative stress and suggests a protective role for GSTA1-1 in JNK-associated apoptosis 
in MEF3T3 cells. Therefore, the assumption that GSTA1-1 might also play some functional  
non-catalytic role in BEN development should be addressed in the future. 
3. Experimental Section 
3.1. Study Participants 
This case-control study comprised 207 patients with Balkan endemic nephropathy and 138 healthy 
controls, residents of endemic settlements with a negative family history for BEN. The BEN group 
consisted of patients who fulfilled criteria for BEN according to Stefanovic et al. [42], after exclusion 
of other kidney diseases. All patients with BEN were recruited in two hemodialysis centers from 
Bosnia and Herzegovina—Republic of Srpska (Bijeljina and Šamac) and one center from the Republic 
of Serbia (Lazarevac). Gender- and age-matched (±2 years) healthy subjects from non-BEN families 
were registered during the screening studies carried out in endemic villages in the same regions from 
January 2012 to December 2012. Subjects invited to the control group were included in this study only 
if no pathological finding was detected by objective examination and routine laboratory analysis. 
Demographic and clinical characteristics were obtained from medical records. All the participants 
provided written informed consent. This study protocol was approved by the Institutional Review 
Board (permission number 29/VI-13), and the research was carried out in compliance with the 
Helsinki Declaration (as revised in 2000).  
3.2. GST Genotyping 
Genomic DNA was isolated from whole blood using the QIAmp
®
 DNA Blood Mini kit  
(Qiagen, Inc., Chatsworth, CA, USA) according to the manufacturer’s protocol. 
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The analysis of GSTA1 C-69T SNP was performed using the polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method, as described previously by Ping et al. [43].  
A 400 bp fragment of GSTA1 gene was amplified with primers: GSTA1 forward primer  
5'-GCATCAGCTTGCCCTTCA-3' and GSTA1 reverse primer 5'-AAACGCTGTCACCGTCCTG-3'. 
The presence of the Eam1104I restriction site yielded two fragments of 308 and 92 bp  
(GSTA1*B), whereas, the absence of restriction site was determined by the presence of a 400 bp 
fragment (GSTA1*A). 
GSTM1 and GSTT1 deletion polymorphisms were determined by multiplex PCR method, as 
described by Abdel-Rahman et al. [44], with some modifications. The following primers used were: 
GSTT1 forward primer 5'-TTCCTTACTGGTCCTCACATCTC-3'; GSTT1 reverse primer  
5'-TCACCGGATCATGGCCAGCA-3'; GSTM1 forward primer 5'-GAACTCCCTGAAAAGCTA 
AAGC-3'; GSTM1 reverse primers: 5'-GTTGGGCTCAAATATACGGTGG-3', and instead of the 
CYP1A1 gene as an internal positive control, β-globin gene primers were used:  
5'-ACACAACTGTGTTCACTAGC-3' and 5'-CAACTTCATCCACGTTCACC-3' [45]. Using these 
primers, the assay does not distinguish between heterozygous or homozygous wild type genotypes; 
therefore, the presence of 215 and 480 bp bands were indicative for the GSTM1 and GSTT1active 
genotype, respectively. Amplification of the β-globin gene was used as the internal positive control 
and produced a 110 bp fragment. 
GSTP1 A1578G (Ile105Val) polymorphism was determined by the previously described PCR-RFLP 
method [46]. GSTP1 forward primer 5'-ACCCCAGGGCTCTATGGGAA-3' and GSTP1 reverse 
primer 5'-TGAGGGCACAAGAAGCCCCT-3' were used to amplify a 176 bp fragment of GSTP1 
gene. After digestion, fragments were separated and three different patterns were obtained: the wild 
genotype Ile/Ile had only a 176 bp band, the homozygous mutant genotype Val/Val is characterized by 
91 and 85 bp products, while the heterozygous genotype Ile/Val yielded three bands (176, 91 and 85 bp). 
Because the assays are extremely robust, quality control procedures were implemented as random 
repeats, water blanks for checking DNA contamination, and orientation markers. Results of 
genotyping for the study were read from the gel by two independent investigators, and at least 20% of 
the samples were randomly repeated. 
3.3. Statistical Analysis 
In the descriptive statistics, we report continuous variables by mean ± standard deviation (SD). We 
used one-way ANOVA for comparing the means of continuous variables. The chi-square (χ2) test was 
used to compare the gender distribution and to test the deviation of genotype distribution from the 
Hardy-Weinberg equilibrium (HWE). Also, the statistical significance of the differences between the 
frequency genotypes of groups was determined using the chi-square test. Two-sided p < 0.05 was 
considered to be statistically significant. 
Binomial logistic regression was used to estimate the odds ratio (OR) and 95% confidence intervals 
(CI) with two-sided p-values for the association between BEN and the studied genotypes, adjusted for 
age and gender. 
The SPSS 17.0 statistical software package (SPSS Inc., Chicago, IL, USA) was used to assess the 
significance of the studied variables. 
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3.4. Molecular Modeling (in Silico) 
The crystal structure of human glutathione transferase A1-1 bound with chlorambucil was 
downloaded from the protein data bank (http:// http://www.rcsb.org/, PDB ID 4HJ2) [47]. The protein 
structure was prepared by deleting water molecules and reducing enzymes into a monomer structure. 
OTA metabolites were covalently bonded to bound GSH, and OTHQ-SG and OTB-SG were produced. 
Conjugates were placed in two starting positions: one with the peptide part of the subunit facing the 
inner part of the protein and another with the peptide part of subunit facing the solvent accessible 
space of the enzyme. All structures were subjected to a minimization procedure in Impact (version 5.8, 
Schrödinger, L.L.C., New York, NY, USA, 2005), using OPLS2005 force field and the Surface 
Generalized Born (SBG) solvation model. During minimization, the following constraints were 
applied: all amino acids occupying a space of more than 18 Å from the ligand were kept frozen and the 
glutathione part of the conjugate was subjected to a constraint of 25.0 kcal/mol force. Truncated 
Newton algorithm with 100 maximum cycles was applied. The resulting structures were furthermore 
subjected to an Impact Dynamics procedure, using the same force field and solvation model and 
constraints, with other parameters set as default values. After that, the final structures were again 
minimized under the same conditions, but this time with 2000 maximum cycles and with the energy 
and gradient convergence criteria set to 1 × 10
−7
 kcal/mol and 0.01 kcal/(mol Å), respectively. 
4. Conclusions 
We found that GSTA1 polymorphism is associated with an increased risk of BEN. 
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